☆ 4.2 Review

Advances in Osteosarcoma

CURRENT OSTEOPOROSIS REPORTS (2023)

Related references

Note: Only part of the references are listed.
Editorial Material Biochemistry & Molecular Biology

Molecular and Translational Research on Bone Tumors

Michela Rossi et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection
Article Engineering, Biomedical

Zinc oxide nanoparticles inhibit osteosarcoma metastasis by downregulating β-catenin via HIF-1α/BNIP3/LC3B-mediated mitophagy pathway

Guanping He et al.

Summary: In this study, it was found that zinc oxide nanoparticles (ZnO NPs) can inhibit osteosarcoma metastasis by degrading beta-catenin through the activation of the HIF-1 alpha/BNIP3/LC3B-mediated mitophagy pathway. The combination of ZnO NPs and the beta-catenin inhibitor ICG-001 showed a synergistic inhibitory effect on osteosarcoma lung metastasis.

BIOACTIVE MATERIALS (2023)

Add to Collection
Article Biotechnology & Applied Microbiology

LncSNHG14 promotes nutlin3a resistance by inhibiting ferroptosis via the miR-206/SLC7A11 axis in osteosarcoma cells

Luoying Li et al.

Summary: Osteosarcoma (OS) is the most common primary osseous malignant tumor in adolescents and children. The standard therapy involves surgery combined with neoadjuvant/post-surgery chemotherapy, but chemoresistance often leads to poor efficacy. In this study, the upregulation of lncRNA SNHG14 was found to contribute to treatment resistance by suppressing ferroptosis in a nutlin3a-resistant OS cell line. Knockdown of lncRNA SNHG14 reversed drug resistance and activated ferroptosis, indicating its role in chemotherapy resistance and ferroptosis inhibition. Targeting lncRNA SNHG14 may provide a new approach to overcome drug resistance and improve treatment efficacy in osteosarcoma.

CANCER GENE THERAPY (2023)

Add to Collection
Article Pharmacology & Pharmacy

Osteosarcoma mechanobiology and therapeutic targets

Zunaira Shoaib et al.

Summary: Osteosarcoma, a common primary bone tumor, is influenced by mechanobiology in its pathogenesis. Mechanobiology-driven therapies can curb tumor progression by altering the physical microenvironment or inhibiting proteins associated with metastasis.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Add to Collection
Article Oncology

Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma

Xi-zhi Wen et al.

Summary: The study aimed to investigate the maximum tolerated doses and dose-limiting toxicities of pegylated liposomal doxorubicin (PEG-LD) and cisplatin combination in patients with metastatic and recurrent osteosarcoma. The MTD of PEG-LD was found to be 50 mg/m(2) with neutropenic fever and stomatitis as DLTs. Overall response rate was 13.3% and disease control rate was 66.7%.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

Add to Collection
Review Oncology

Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma

Kunzhe Wu et al.

Summary: Osteosarcoma is the most common primary bone tumor in children and young people. Traditional treatment methods have limitations, and nanometer-sized platform-based chemotherapeutic delivery is a promising alternative therapy that offers accurate drug delivery and bone defect repair. This review provides a brief summary of various nanoplatforms, discusses their shortcomings and proposed solutions, and explores the application prospects of nanoplatforms in osteosarcoma treatment.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection
Review Oncology

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges

Miguel Garcia-Pardo et al.

Summary: The identification of genomic alterations has revolutionised the management of solid tumor patients in the era of precision medicine. Recent advances in the detection and characterisation of circulating tumor DNA (ctDNA) have enabled liquid biopsy to be integrated into clinical practice, serving as a promising biomarker for prognostication, monitoring disease response, detection of minimal residual disease and early diagnosis. This Review discusses the current and future clinical applications of ctDNA primarily in non-small cell lung cancer and other solid tumors.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection
Article Oncology

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

Enriqueta Felip et al.

Summary: This study assessed the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of cetrelimab in patients with advanced/refractory solid tumors. The results showed that cetrelimab had favorable pharmacokinetic and pharmacodynamic characteristics, as well as clinical activity, in immune-sensitive advanced cancers.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

Add to Collection
Article Medical Laboratory Technology

Single-Cell Phenotypic and Molecular Characterization of Circulating Tumor Cells Isolated from Cryopreserved Peripheral Blood Mononuclear Cells of Patients with Lung Cancer and Sarcoma

Marta Vismara et al.

Summary: Isolating CTCs from cryopreserved PBMCs allows for retrospective enumeration and molecular characterization, with EpCAM-independent strategies performing equally in capturing CTCs. Cells isolated from frozen PBMCs are representative of CTCs from whole blood and long-term storage does not affect CTC recovery efficacy. Detection of target mutations is feasible in CTC-enriched samples derived from stored PBMCs, offering potential for personalized therapy and multicenter studies.

CLINICAL CHEMISTRY (2022)

Add to Collection
Article Oncology

Lung fibrosis is a novel therapeutic target to suppress lung metastasis of osteosarcoma

Yoshihiro Yui et al.

Summary: The prognosis of patients with metastatic and recurrent osteosarcoma has not improved due to the lack of effective treatment for lung metastasis. However, antifibrotic agents may be a potential therapeutic target for suppressing lung metastasis of osteosarcoma cells, as they rely on scaffold in the soft tissue environment.

INTERNATIONAL JOURNAL OF CANCER (2022)

Add to Collection
Article Biotechnology & Applied Microbiology

Convallatoxin suppresses osteosarcoma cell proliferation, migration, invasion, and enhances osteogenic differentiation by downregulating parathyroid hormone receptor 1 (PTHR1) expression and inactivating Wnt/β-catenin pathway

Xin Liu et al.

Summary: The study showed that convallatoxin suppressed the proliferation, migration, and invasion of osteosarcoma cells, while promoting their osteogenic differentiation. It achieved these effects by inhibiting PTHR1 and the Wnt/beta-catenin pathway.

BIOENGINEERED (2022)

Add to Collection
Article Medicine, General & Internal

Safety, tolerability, and anti-fibrotic efficacy of the CBP/I3-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study

Kiminori Kimura et al.

Summary: This study assessed the safety tolerability and anti-fibrotic effects of PRI-724 in patients with HCV-and HBV-induced cirrhosis. The results showed that PRI-724 did not significantly decrease hepatic fibrosis, but it improved liver stiffness, Model for End-stage Liver Disease score, and serum albumin level significantly.

EBIOMEDICINE (2022)

Add to Collection
Article Oncology

Inhibiting Endothelin Receptors with Macitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma

Javier Munoz-Garcia et al.

Summary: Current osteosarcoma therapy is hindered by drug resistance and metastasis. Inhibiting bone resorption and endothelin signaling may provide a solution. Research suggests that inhibiting endothelin signaling can significantly reduce the formation of mineralized tissue and metastasis in osteosarcoma, without affecting sensitivity to chemotherapy. Macitentan, an endothelin receptor inhibitor, shows promise as a therapeutic adjuvant for osteosarcoma.

CANCERS (2022)

Add to Collection
Review Oncology

Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment

Duoli Xie et al.

Summary: Osteosarcoma is an aggressive bone cancer with unknown molecular pathways, making it difficult to improve patient survival. Conventional therapies have severe side effects due to the lack of selectivity for malignant tissue. Researchers are exploring targeted treatment methods by combining specific ligands and chemotherapeutic agents to treat tumor cells.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection
Article Oncology

Single-Cell Profiling of Tumor Microenvironment Heterogeneity in Osteosarcoma Identifies a Highly Invasive Subcluster for Predicting Prognosis

Junfeng Guo et al.

Summary: This study identified cellular communication and established a risk regression model in osteosarcoma, revealing the complex regulatory network in the microenvironment and providing new strategies for diagnosis and treatment.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection
Article Biotechnology & Applied Microbiology

Therapeutic Effects of Zoledronic Acid-Loaded Hyaluronic Acid/Polyethylene Glycol/Nano-Hydroxyapatite Nanoparticles on Osteosarcoma

Yan Xu et al.

Summary: The innovative nano-drug delivery system of ZOL nanoparticles has been found to effectively inhibit the proliferation of osteosarcoma cells with low cytotoxicity on normal cells, showing potential for local treatment to prevent tumor recurrence.

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2022)

Add to Collection
Article Medicine, General & Internal

Osteosarcoma A

Hannah C. Beird et al.

Summary: Osteosarcoma is the most common primary malignant bone tumor with a bimodal incidence peaking at 18 and 60 years of age. It is more common in males and is driven by genetic factors related to bone formation leading to malignant progression and metastasis. Screening is currently focused on high-risk groups, and the prognosis for patients with metastatic disease remains poor.

NATURE REVIEWS DISEASE PRIMERS (2022)

Add to Collection
Article Oncology

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial

Neeta Somaiah et al.

Summary: This trial evaluates the efficacy and safety of durvalumab, an anti-PD-L1 drug, and tremelimumab, an anti-CTLA-4 drug, for multiple subtypes of metastatic sarcomas. The combination treatment demonstrates active potential for advanced or metastatic sarcoma and should be further investigated in specific subsets in future trials.

LANCET ONCOLOGY (2022)

Add to Collection
Review Oncology

Ferroptosis in osteosarcoma: A promising future

Xiang Liu et al.

Summary: This paper reviews the regulatory mechanism and research progress of ferroptosis in osteosarcoma, providing new insights for clinical treatment.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection
Article Cell Biology

Self-Assembling Imageable Silk Hydrogels for the Focal Treatment of Osteosarcoma

Zhibin Peng et al.

Summary: A self-assembling imageable silk hydrogel has been developed for the treatment of osteosarcoma. Iodine has been shown to induce apoptosis in osteosarcoma cells, and the silk hydrogel has demonstrated good therapeutic efficacy and biosafety in the treatment of the disease.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Add to Collection
Article Oncology

Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential

Yang Wen et al.

Summary: This review discusses the use of immune checkpoint inhibitors (ICIs) in the treatment of osteosarcoma and their related mechanisms. Osteosarcoma treatment has had limited progress over the years, but the advent of ICIs provides a new therapeutic strategy. The current mechanisms of resistance to ICIs therapy in osteosarcoma are summarized, along with strategies to improve their efficacy and potential predictive biomarkers.

CANCER LETTERS (2022)

Add to Collection
Article Medicine, Research & Experimental

HIAYA CHAT study protocol: a randomized controlled trial of a health insurance education intervention for newly diagnosed adolescent and young adult cancer patients

Karely Mann et al.

Summary: This study is a randomized controlled trial testing a virtual health insurance education intervention for adolescent and young adult cancer patients, aiming to evaluate its feasibility and acceptability.

TRIALS (2022)

Add to Collection
Review Biochemistry & Molecular Biology

Three-dimensional in vitro culture models in oncology research

Camille Jubelin et al.

Summary: Cancer is a complex disease that requires multidimensional models to understand its development and drug response. Three-dimensional cell culture models, compared to traditional two-dimensional cultures, better mimic the biological behavior of tumor cells and provide a better platform for studying therapeutic escape and drug resistance.

CELL AND BIOSCIENCE (2022)

Add to Collection
Review Immunology

Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality

Lei Yu et al.

Summary: This article reviews the positive effects of hypoxia in osteosarcoma and discusses the role of immunotherapy in the tumor microenvironment. It suggests that immunotherapy may represent an innovative approach for the treatment of osteosarcoma patients.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Review Biotechnology & Applied Microbiology

Recent advances in hydrogels-based osteosarcoma therapy

Hao Tian et al.

Summary: Osteosarcoma is a common bone tumor in adolescents and traditional treatment methods have drawbacks. Hydrogels can be used as a platform for treating osteosarcoma and promoting bone regeneration.

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2022)

Add to Collection
Article Oncology

Lipopolysaccharide-binding protein expression is associated to the metastatic status of osteosarcoma patients

Clement J. F. Heymann et al.

Summary: Osteosarcoma is a rare bone tumor with high genetic and cell heterogeneity. This study found the presence of Gram-negative bacteria in osteosarcoma tissues and demonstrated significant differences in their levels according to the metastatic status. This tumor-associated microbiome may provide new insights into the development of therapeutic approaches for osteosarcoma.

JOURNAL OF BONE ONCOLOGY (2022)

Add to Collection
Review Oncology

Advances in the Biological Functions and Mechanisms of miRNAs in the Development of Osteosarcoma

Zihe Dong et al.

Summary: This paper reviews the role of microRNAs in the pathogenesis of osteosarcoma and their clinical value, aiming to provide a new research direction for diagnosing and treating osteosarcoma and achieving a better prognosis.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2022)

Add to Collection
Article Biochemistry & Molecular Biology

Iron plays a role in sulfasalazine-induced ferroptosis with autophagic flux blockage in K7M2 osteosarcoma cells

Junyu Liu et al.

Summary: This study uncovers the essential role of iron in the effects of sulfasalazine on osteosarcoma cells. Iron exacerbates cell death induced by sulfasalazine and affects cell cycle, mitochondria morphology and function, and the redox system. Furthermore, iron induces dysfunction of autophagic activity in sulfasalazine-treated cells.

METALLOMICS (2022)

Add to Collection
Article Nanoscience & Nanotechnology

Highly Adhesive, Stretchable and Breathable Gelatin Methacryloyl-based Nanofibrous Hydrogels for Wound Dressings

Yumin Liu et al.

Summary: A highly adhesive, stretchable, and breathable nanofibrous hydrogel was developed using an in situ hybrid cross-linking strategy of dopamine and gelatin methacryloyl. The optimized nanofibrous hydrogel showed excellent mechanical properties and adhesive strength, while also promoting cell growth and accelerating wound healing.

ACS APPLIED BIO MATERIALS (2022)

Add to Collection
Review Medicine, General & Internal

NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma ? a case report and review of the literature

Laure Nuytemans et al.

Summary: This study presents a case of a metastatic osteosarcoma patient who did not respond to standard chemotherapy and received dual checkpoint inhibition therapy. The patient showed stabilization of retrocardiac tumor masses with the treatment, indicating potential efficacy. The addition of radiotherapy was needed for a growing bone lesion, and overall the patient's condition improved.

ACTA CLINICA BELGICA (2021)

Add to Collection
Review Pharmacology & Pharmacy

Bone sarcomas in the immunotherapy era

Marie-Francoise Heymann et al.

Summary: Bone sarcomas primarily occur in children and adolescents, with recent developments focusing on understanding the immune system's role in the oncologic process. Immunotherapies have not shown significant improvements, highlighting the need to improve tumor micro-environment characterization to enhance immune therapeutic responses.

BRITISH JOURNAL OF PHARMACOLOGY (2021)

Add to Collection
Article Chemistry, Multidisciplinary

Endogenous H2S-Activated Orthogonal Second Near-Infrared Emissive Nanoprobe for In Situ Ratiometric Fluorescence Imaging of Metformin-Induced Liver Injury

Zhiming Deng et al.

Summary: The hypoglycemic drug metformin has shown potential for treating various diseases beyond diabetes, but overdose can lead to serious liver injury. Developing intelligent NIR-II emitting nanoprobes using endogenous H2S as a trigger for monitoring metformin-induced hepatotoxicity is desirable, and a specific probe has been successfully designed for in situ ratiometric monitoring.

ACS NANO (2021)

Add to Collection
Review Oncology

Regulation of PD-L1 expression in the tumor microenvironment

Ming Yi et al.

Summary: PD-L1 expression is regulated by various factors, impacting the treatment effect and patient selection. Understanding the mechanisms of PD-L1 regulation helps enhance the efficacy of immunotherapy.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Article Biochemistry & Molecular Biology

MicroRNA-1287-5p promotes ferroptosis of osteosarcoma cells through inhibiting GPX4

Zhengquan Xu et al.

Summary: miR-1287-5p promotes ferroptosis of osteosarcoma cells by inhibiting GPX4 and increases sensitivity to cisplatin chemotherapy, providing a new approach for the treatment of human osteosarcoma.

FREE RADICAL RESEARCH (2021)

Add to Collection
Article Immunology

TIM-3: An update on immunotherapy

Lizhen Zhao et al.

Summary: TIM-3, originally found on Th1 cells, has been discovered to be expressed on various immune cells with different ligands and effects. It plays a significant role in autoimmune diseases, chronic viral infections and tumors. Targeting TIM-3 is a promising approach in current immunotherapy, especially in combination with other immune checkpoint blockers.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection
Article Oncology

Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial

Kjetil Boye et al.

Summary: This study aimed to evaluate the activity and safety of the PD-1 antibody pembrolizumab in adult patients with advanced osteosarcoma. The results showed that pembrolizumab was well-tolerated but did not demonstrate clinically significant antitumor activity in the patients. Further trials with immunomodulatory agents in osteosarcoma should explore combination strategies in patients selected based on molecular profiles associated with response.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection
Article Oncology

Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs

Chenglong Chen et al.

Summary: Immunotherapy has shown promising efficacy in treating osteosarcoma, especially for metastatic or recurrent cases. Recent advancements in biomarker development have increased the number of patients benefiting from immunotherapies, offering hope to patients in need of new treatments.

CANCER LETTERS (2021)

Add to Collection
Article Multidisciplinary Sciences

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

Darci Phillips et al.

Summary: This study reveals a spatial biomarker that utilizes immune and cancer cell topography to predict response to PD-1 blockade in cutaneous T cell lymphomas. The biomarker is strongly correlated with the functional immune state of the tumor microenvironment, T cell function, and tumor cell-specific chemokine recruitment.

NATURE COMMUNICATIONS (2021)

Add to Collection
Review Oncology

Targeting ferroptosis in osteosarcoma

Jiazheng Zhao et al.

Summary: Osteosarcoma, the most common primary bone tumor in children and adolescents, is closely associated with ferroptosis, a mode of regulated cell death that can play a key role in treatment, offering a new therapeutic strategy.

JOURNAL OF BONE ONCOLOGY (2021)

Add to Collection
Review Oncology

In vitro three-dimensional cell cultures for bone sarcomas

Javier Munoz-Garcia et al.

Summary: Bone sarcomas, rare tumour entities arising from the mesenchyme, are highly heterogeneous at cellular, genetic, and epigenetic levels. Despite the lack of significant therapeutic improvements in the last four decades, new 3D culture methods show promise in providing more relevant in vitro models for studying these primary bone sarcomas.

JOURNAL OF BONE ONCOLOGY (2021)

Add to Collection
Article Oncology

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients

Angelika M. Starzer et al.

Summary: The study demonstrates that tumor DNA methylation profiles may serve as a predictive marker for response to anti-PD-1 ICI therapy in patients with sarcoma. Analysis of methylation data helps to identify differences between responders and non-responders, aiding in predicting treatment outcomes.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Chemistry, Medicinal

ICG-001, an Inhibitor of the β-Catenin and cAMP Response Element-Binding Protein Dependent Gene Transcription, Decreases Proliferation but Enhances Migration of Osteosarcoma Cells

Geoffroy Danieau et al.

Summary: This study analyzed the effects of ICG-001 on three human osteosarcoma cell lines and found that ICG-001 treatment significantly inhibited cell proliferation and induced cell cycle arrest, but unexpectedly increased cell migration. In a mouse model of osteosarcoma, ICG-001 did not affect tumor growth but significantly increased metastatic dissemination to the lungs.

PHARMACEUTICALS (2021)

Add to Collection
Article Biochemistry & Molecular Biology

Tirapazamine suppress osteosarcoma cells in part through SLC7A11 mediated ferroptosis

Yihua Shi et al.

Summary: This study investigated the inhibitory effect and mechanism of TPZ in osteosarcoma, demonstrating that TPZ can induce ferroptosis and inhibit the proliferation and migration of osteosarcoma cells through inhibition of SLC7A11.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)

Add to Collection
Review Biochemistry & Molecular Biology

Osteosarcoma and Metastasis Associated Bone Degradation-A Tale of Osteoclast and Malignant Cell Cooperativity

Kirstine Sandal Norregaard et al.

Summary: Cancer-induced bone degradation involves osteoclasts and cancer cells contributing to the degradation process and interacting with each other in the pathological process of primary bone cancers and bone metastases.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection
Article Multidisciplinary Sciences

Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden

Peter Peneder et al.

Summary: The study introduces an integrated genetic/epigenetic analysis method for liquid biopsy of pediatric tumors with few genetic aberrations. The LIQUORICE algorithm is developed for detecting and classifying circulating tumor DNA based on cancer-specific chromatin signatures. The research highlights the potential value of cfDNA fragmentation patterns as prognostic biomarkers in Ewing sarcoma and makes liquid biopsy benefits more accessible for childhood cancers.

NATURE COMMUNICATIONS (2021)

Add to Collection
Review Oncology

New perspective into mesenchymal stem cells: Molecular mechanisms regulating osteosarcoma

Xingyu Chang et al.

Summary: Mesenchymal stem cells play a crucial role in osteosarcoma by interacting with the tumor microenvironment and facilitating cellular communication. They can be modified into biological carriers for drug delivery and gene therapy targeting osteosarcoma.

JOURNAL OF BONE ONCOLOGY (2021)

Add to Collection
Article Oncology

Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices

Henrietta O. Fasanya et al.

Summary: The study evaluated the efficacy of GD2, GD3, and CSV as markers for capturing osteosarcoma cells through flow cytometry and a microfluidic device. The combination of biomarkers GD2 + CSV demonstrated a high capture efficiency of approximately 80%, with the detection of a significant number of CTCs in patient samples.

JOURNAL OF BONE ONCOLOGY (2021)

Add to Collection
Article Veterinary Sciences

Convallatoxin, the primary cardiac glycoside in lily of the valley (Convallaria majalis), induces tissue factor expression in endothelial cells

Mami Morimoto et al.

Summary: This study demonstrated that Convallotoxin (CNT) can induce the expression of tissue factor (TF) in endothelial cells, leading to a hypercoagulable state. The findings contribute to understanding the mechanisms underlying CNT-induced hypercoagulability.

VETERINARY MEDICINE AND SCIENCE (2021)

Add to Collection
Article Engineering, Biomedical

Gold nanorods and nanohydroxyapatite hybrid hydrogel for preventing bone tumor recurrence via postoperative photothermal therapy and bone regeneration promotion

Jinfeng Liao et al.

Summary: Osteosarcoma, a malignant bone tumor that often occurs in adolescents, poses challenges in complete surgical removal leading to high recurrence rates and metastasis. A novel hydrogel with photothermal properties has been developed for postoperative tumor eradication and bone regeneration, showing promising dual functions in tumor therapy and tissue repair.

BIOACTIVE MATERIALS (2021)

Add to Collection
Article Oncology

Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes

John A. Ligon et al.

Summary: The study found that osteosarcoma pulmonary metastases (PMs) exhibit immune exclusion with an accumulation of tumor-infiltrating lymphocytes at the PM interface, which produce effector cytokines. Additionally, there were alternatively activated macrophages and polymorphonuclear myeloid-derived suppressor cells in different distributions between the center and edge of the PMs. These findings suggest potential cooperative immunosuppressive mechanisms that could be targeted for successful immunotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Oncology

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Kazushige Yoshida et al.

BMC CANCER (2020)

Add to Collection
Article Cell Biology

Long noncoding RNA LINC01278 favors the progression of osteosarcoma via modulating miR-133a-3p/PTHR1 signaling

Zhigang Qu et al.

JOURNAL OF CELLULAR PHYSIOLOGY (2020)

Add to Collection
Article Plant Sciences

Convallatoxin promotes apoptosis and inhibits proliferation and angiogenesis through crosstalk between JAK2/STAT3 (T705) and mTOR/STAT3 (S727) signaling pathways in colorectal cancer

Zhi Hong Zhang et al.

PHYTOMEDICINE (2020)

Add to Collection
Article Multidisciplinary Sciences

Immuno-genomic landscape of osteosarcoma

Chia-Chin Wu et al.

NATURE COMMUNICATIONS (2020)

Add to Collection
Article

Tumor secreted ANGPTL2 facilitates recruitment of neutrophils to the lung to promote lung pre-metastatic niche formation and targeting ANGPTL2 signaling affects metastatic disease

Manish Charan et al.

Oncotarget (2020)

Add to Collection
Article Multidisciplinary Sciences

The human tumor microbiome is composed of tumor type-specific intracellular bacteria

Deborah Nejman et al.

SCIENCE (2020)

Add to Collection
Article Oncology

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial

Kara L. Davis et al.

LANCET ONCOLOGY (2020)

Add to Collection
Review Cell Biology

The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem

Isabelle Corre et al.

CELLS (2020)

Add to Collection
Article Cell Biology

Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer

Xiaoguang Liu et al.

NATURE CELL BIOLOGY (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Osteosarcoma-Derived Extracellular Vesicles Induce Lung Fibroblast Reprogramming

Alekhya Mazumdar et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection
Article Endocrinology & Metabolism

Bisphosphonates in common pediatric and adult bone sarcomas

Marie-Francoise Heymann et al.

BONE (2020)

Add to Collection
Review Medicine, Research & Experimental

Sarcoma treatment in the era of molecular medicine

Thomas G. P. Grunewald et al.

EMBO MOLECULAR MEDICINE (2020)

Add to Collection
Article

Can Denosumab be used in combination with Doxorubicin in Osteosarcoma?

Francesca Punzo et al.

Oncotarget (2020)

Add to Collection
Article Oncology

Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma A Phase 1/2 Nonrandomized Clinical Trial

Seth M. Pollack et al.

JAMA ONCOLOGY (2020)

Add to Collection
Article Biotechnology & Applied Microbiology

Thermogel Delivers Oxaliplatin and Alendronatein situfor Synergistic Osteosarcoma Therapy

Yifu Sun et al.

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2020)

Add to Collection
Article Multidisciplinary Sciences

Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma

Yan Zhou et al.

NATURE COMMUNICATIONS (2020)

Add to Collection
Article Oncology

Exploring the Role of Osteosarcoma-Derived Extracellular Vesicles in Pre-Metastatic Niche Formation and Metastasis in the 143-B Xenograft Mouse Osteosarcoma Model

Alekhya Mazumdar et al.

CANCERS (2020)

Add to Collection
Article Biochemical Research Methods

12b80-Hydroxybisphosphonate Linked Doxorubicin: Bone Targeted Strategy for Treatment of Osteosarcoma

Emmanuelle David et al.

BIOCONJUGATE CHEMISTRY (2019)

Add to Collection
Review Immunology

Immune Function and Diversity of Osteoclasts in Normal and Pathological Conditions

Maria-Bernadette Madel et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection
Article Oncology

Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma

Li Minghui et al.

JOURNAL OF BONE ONCOLOGY (2019)

Add to Collection
Review Oncology

Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice

Alexandros Stamatopoulos et al.

JOURNAL OF BONE ONCOLOGY (2019)

Add to Collection
Article Cell Biology

The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma

Marie-Francoise Heymann et al.

CELLULAR IMMUNOLOGY (2019)

Add to Collection
Article Oncology

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study

A. Le Cesne et al.

EUROPEAN JOURNAL OF CANCER (2019)

Add to Collection
Review Pharmacology & Pharmacy

Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality?

Hannah K. Brown et al.

DRUG DISCOVERY TODAY (2019)

Add to Collection
Review Medicine, Research & Experimental

Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity

Marta Tellez-Gabriel et al.

THERANOSTICS (2019)

Add to Collection
Article Gastroenterology & Hepatology

Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin-6/STAT3 signaling pathway

Jiwei Zhang et al.

HEPATOLOGY (2018)

Add to Collection
Article Nanoscience & Nanotechnology

Zinc oxide nanoparticles induce toxicity in CAL 27 oral cancer cell lines by activating PINK1/Parkin-mediated mitophagy

Jianfeng Wang et al.

INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)

Add to Collection
Article Nanoscience & Nanotechnology

Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells

Fangyi Chen et al.

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2018)

Add to Collection
Article

Detection of circulating tumor DNA in patients with osteosarcoma

David M. Barris et al.

Oncotarget (2018)

Add to Collection
Article Oncology

Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases

Pooja Dhupkar et al.

CANCER MEDICINE (2018)

Add to Collection
Article Oncology

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group

David S. Shulman et al.

BRITISH JOURNAL OF CANCER (2018)

Add to Collection
Article Cell Biology

Adaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth

Wu Zhang et al.

CELL REPORTS (2018)

Add to Collection
Article

Targeting the Wnt/β-catenin pathway in human osteosarcoma cells

Fang Fang et al.

Oncotarget (2018)

Add to Collection
Article Oncology

The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases

Benjamin Navet et al.

CANCERS (2018)

Add to Collection
Article Oncology

Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer

Pranavi Koppula et al.

CANCER COMMUNICATIONS (2018)

Add to Collection
Article Medicine, Research & Experimental

IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis

Amy C. Gross et al.

JCI INSIGHT (2018)

Add to Collection
Review Endocrinology & Metabolism

Biology of Bone Sarcomas and New Therapeutic Developments

Hannah K. Brown et al.

CALCIFIED TISSUE INTERNATIONAL (2018)

Add to Collection
Article Oncology

Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy

Antoine Chalopin et al.

JOURNAL OF BONE ONCOLOGY (2018)

Add to Collection
Article Oncology

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi et al.

LANCET ONCOLOGY (2017)

Add to Collection
Article Medicine, Research & Experimental

Role of RANK and Akt1 activation in human osteosarcoma progression: A clinicopathological study

Jianxi Zhu et al.

EXPERIMENTAL AND THERAPEUTIC MEDICINE (2017)

Add to Collection
Article Oncology

All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages

Qian Zhou et al.

CANCER IMMUNOLOGY RESEARCH (2017)

Add to Collection
Article Oncology

Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)

Andres Redondo et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)

Add to Collection
Review Oncology

Mesenchymal stroma: Role in osteosarcoma progression

Margherita Cortini et al.

CANCER LETTERS (2017)

Add to Collection
Article Oncology

Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression

S. Rubina Baglio et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection
Article Physiology

Endothelin signaling regulates mineralization and posttranscriptionally regulates SOST in TMOb cells via miR 126-3p

Michael G. Johnson et al.

PHYSIOLOGICAL REPORTS (2017)

Add to Collection
Review Oncology

Cancer stem cells in osteosarcoma

Hannah K. Brown et al.

CANCER LETTERS (2017)

Add to Collection
Article Oncology

Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors

Melinda S. Merchant et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection
Article Oncology

Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial

Sophie Piperno-Neumann et al.

LANCET ONCOLOGY (2016)

Add to Collection
Article Oncology

Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma

Clotilde Dumars et al.

ONCOTARGET (2016)

Add to Collection
Review Biochemistry & Molecular Biology

Bone microenvironment signals in osteosarcoma development

Arantzazu Alfranca et al.

CELLULAR AND MOLECULAR LIFE SCIENCES (2015)

Add to Collection
Article Oncology

Receptor activator of nuclear factor κB expression is a prognostic factor in human osteosarcoma

Klemens Trieb et al.

ONCOLOGY LETTERS (2015)

Add to Collection
Article Multidisciplinary Sciences

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

Michal Kovac et al.

NATURE COMMUNICATIONS (2015)

Add to Collection
Article Oncology

RANK and RANK ligand expression in primary human osteosarcoma

Daniel Branstetter et al.

JOURNAL OF BONE ONCOLOGY (2015)

Add to Collection
Article Oncology

Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells

Arun Satelli et al.

CANCER RESEARCH (2014)

Add to Collection
Article Oncology

STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma

Bing Tu et al.

CANCER LETTERS (2012)

Add to Collection
Article Medicine, General & Internal

Common Musculoskeletal Tumors of Childhood and Adolescence

Carola A. S. Arndt et al.

MAYO CLINIC PROCEEDINGS (2012)

Add to Collection
Article Oncology

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

Evan J. Lipson et al.

CLINICAL CANCER RESEARCH (2011)

Add to Collection
Article Endocrinology & Metabolism

Formulated siRNAs Targeting Rankl Prevent Osteolysis and Enhance Chemotherapeutic Response in Osteosarcoma Models

Julie Rousseau et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2011)

Add to Collection
Article Oncology

Loss of Osteoclasts Contributes to Development of Osteosarcoma Pulmonary Metastases

Liliana Endo-Munoz et al.

CANCER RESEARCH (2010)

Add to Collection
Article Multidisciplinary Sciences

Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence

Pierre Perrot et al.

PLOS ONE (2010)

Add to Collection
Article Oncology

Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma

Francois Lamoureux et al.

CANCER RESEARCH (2009)

Add to Collection
Article Oncology

Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption

Francois Lamoureux et al.

CANCER RESEARCH (2007)

Add to Collection
Article Oncology

Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B

K. Mori et al.

JOURNAL OF PATHOLOGY (2007)

Add to Collection
Article Pharmacology & Pharmacy

Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status

B. Ory et al.

MOLECULAR PHARMACOLOGY (2007)

Add to Collection
Article Endocrinology & Metabolism

Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma

D Heymann et al.

BONE (2005)

Add to Collection
Review Biochemistry & Molecular Biology

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling

S Theoleyre et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2004)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.